APA (7th ed.) Citation

T, Y., K, M., T, K., S, K., T, T., R, M., . . . T, K. (2026). A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: Results from the JK-FOOT consortium. Cancer immunology, immunotherapy : CII, 75(3), . https://doi.org/10.1007/s00262-025-04288-6

Chicago Style (17th ed.) Citation

T, Yanagisawa, et al. "A Real-world Comparison of Nivolumab Plus Cabozantinib and Pembrolizumab Plus Lenvatinib Focusing on Safety Outcomes in Metastatic Renal Cell Carcinoma: Results from the JK-FOOT Consortium." Cancer Immunology, Immunotherapy : CII 75, no. 3 (2026). https://doi.org/10.1007/s00262-025-04288-6.

MLA (9th ed.) Citation

T, Yanagisawa, et al. "A Real-world Comparison of Nivolumab Plus Cabozantinib and Pembrolizumab Plus Lenvatinib Focusing on Safety Outcomes in Metastatic Renal Cell Carcinoma: Results from the JK-FOOT Consortium." Cancer Immunology, Immunotherapy : CII, vol. 75, no. 3, 2026, https://doi.org/10.1007/s00262-025-04288-6.